The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo

Journal of Immunology

Volumn 170, Issue 6, 2003, Pages 2949-2955

  Yuan, Xueli ^a   Salama, Alan D ^a   Dong, Victor ^a   Schmitt, Isabela ^a   Najafian, Nader ^a   Chandraker, Anil ^a   Akiba, Hisaya ^b   Yagita, Hideo ^b   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD134 LIGAND; CD28 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; HLA B7 ANTIGEN; LIGAND; MONOCLONAL ANTIBODY; RAPAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOINCOMPATIBILITY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN TRANSPLANTATION; T LYMPHOCYTE;

EID: 0037443415     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.6.2949     Document Type: Article

References (51)

1. Lin, H., S. F. Bolling, P. S. Linsley, R. Q. Wei, D. Gordon, C. B. Thompson, and L. A. Turka. 1993. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178:1801.
2. Sayegh, M. H., E. Akalin, W. W. Hancock, M. E. Russell, C. B. Carpenter, P. S. Linsley, and L. A. Turka. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1869.
3. Sayegh, M. H., X. G. Zheng, C. Magee, W. W. Hancock, and L. A. Turka. 1997. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 64:1646.
4. Kishimoto, K., V. M. Dong, S. Issazadeh, E. V. Fedoseyeva, A. M. Waaga, A. Yamada, M. Sho, G. Benichou, H. Auchincloss, Jr., M. J. Grusby, et al. 2000. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106:63.
5. Russell, M. E., W. W. Hancock, E. Akalin, A. F. Wallace, T. Glysing-Jensen, T. A. Willett, and M. H. Sayegh. 1996. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 97:833.
6. Chandraker, A., H. Azuma, K. Nadeau, C. B. Carpenter, N. L. Tilney, W. W. Hancock, and M. H. Sayegh. 1998. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J. Clin. Invest. 101:2309.
7. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
8. Hale, D. A., R. Gottschalk, T. Maki, and A. P. Monaco. 1997. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation 64:897.
9. -/- mice independent of the CD40/CD40L costimulatory pathway. Transplant Immunol. 9:13.
10. Malm, H., M. Corbascio, C. Osterholm, S. Cowan, C. P. Larsen, T. C. Pearson, and H. Ekberg. 2002. CTLA4ig induces long-term graft survival of allogeneic skin grafts and totally inhibits T-cell proliferation in LFA-1-deficient mice. Transplantation 73:293.
11. Shimizu, K., U. Schonbeck, F. Mach, P. Libby, and R. N. Mitchell. 2000. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J. Immunol. 165:3506.
12. Yamada, A., K. Kishimoto, V. M. Dong, M. Sho, A. D. Salama, N. G. Anosova, G. Benichou, D. A. Mandelbrot, A. H. Sharpe, L. A. Turka, et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. J. Immunol. 167:140.
13. Yamada, A., A. D. Salama, and M. H. Sayegh. 2002. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13:559.
14. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286.
15. Yamada, A., and M. H. Sayegh. 2002. The CD154-CD40 costimulatory pathway in transplantation. Transplantation 73:S36.
16. Kirk, A. D., D. M. Harlan, N. N. Armstrong, T. A. Davis, V. Dong, G. S. Gray, X. Hong, D. Thomas, J. H. Fechner, and S. J. Knechtle. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94:8789.
17. Kirk, A. D, L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechner, Jr., R. L. Germond, R. L. Kampen, N. B. Patterson, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5:686.
18. t detected only on CD4-positive T blasts. Mol. Immunol. 24:1281.
19. Calderhead, D. M., J. E. Buhlmann, A. J. van den Eertwegh, E. Claassen, R. J. Noelle, and H. P. Fell. 1993. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol. 151:5261.
20. Latza, U., H. Durkop, S. Schnittger, J. Ringeling, F. Eitelbach, M. Hummel, C. Fonatsch, and H. Stein. 1994. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur. J. Immunol. 24:677.
21. Al-Shamkhani, A., M. L. Birkeland, M. Puklavec, M. H. Brown, W. James, and A. N. Barclay. 1996. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26:1695.
22. Ohshima, Y., Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G. Delespesse. 1997. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159:3838.
23. Brocker, T., A. Gulbranson-Judge, S. Flynn, M. Riedinger, C. Raykundalia, and P. Lane. 1999. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29:1610.
24. Imura, A., T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama. 1996. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183:2185.
25. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. OX40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510.
26. Gramaglia, I., A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:3043.
27. Stuber, E., and W. Strober. 1996. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med. 183:979.
28. Nakae, S., M. Asano, R. Horai, N. Sakaguchi, and Y. Iwakura. 2001. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J. Immunol. 167:90.
29. + spinal cord T cells of Lewis rats with EAE. J. Neurosci. Res. 44:562.
30. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J. Neurosci. Res. 43:42.
31. + T lymphocytes in chronic synovitis. Br. J. Rheumatol. 37:584.
32. Yoshioka, T., A. Nakajima, H. Akiba, T. Ishiwata, G. Asano, S. Yoshino, H. Yagita, and K. Okumura. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30:2815.
33. Matsumura, Y., A. Imura, T. Hori, T. Uchiyama, and S. Imamura. 1997. Localization of OX40/gp34 in inflammatory skin diseases: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch. Dermatol. Res. 289:653.
34. Tittle, T. V., A. D. Weinberg, C. N. Steinkeler, and R. T. Maziarz. 1997. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 89:4652.
35. Weinberg, A. D., K. W. Wegmann, C. Funatake, and R. H. Whitham. 1999. Blocking OX40/OX40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162:1818.
36. Nohara, C., H. Akiba, A. Nakajima, A. Inoue, C. S. Koh, H. Ohshima, H. Yagita, Y. Mizuno, and K. Okumura. 2001. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J. Immunol. 166:2108.
37. Chitnis, T., N. Najafian, K. A. Abdallah, V. Dong, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2001. CD28-independent induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 107:575.
38. Satake, Y., H. Akiba, K. Takeda, M. Atsuta, H. Yagita, and K. Okumura. 2000. Characterization of rat OX40 ligand by monoclonal antibody. Biochim. Biophys. Acta 270:1041.
39. Dong, V. M., X. Yuan, A. J. Coito, A. M. Waaga, M. H. Sayegh, and A. Chandraker. 2002. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 73:1310.
40. Yuan, X., V. M. Dong, A. J. Coito, A. M. Waaga, A. D. Salama. C. D. Benjamin, M. H. Sayegh, and A. Chandraker. 2002. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation 73:1736.
41. Maeda, K., T. Sato, M. Azuma, H. Yagita, and K. Okumura. 1997. Characterization of rat CD80 and CD86 by molecular cloning and mAb. Int. Immunol. 9:993.
42. + T cells. Int. Immunol. 10:453.
43. Flynn, S., K. M. Toellner, C. Raykundalia, M. Goodall, and P. Lane. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and up-regulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297.
44. Kjaergaard, J., J. Tanaka, J. A. Kim, K. Rothchild, A. Weinberg, and S. Shu. 2000. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60:5514.
45. Bansal-Pakala, P., A. G. Jember, and M. Croft. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907.
46. Weinberg, A. D. 2002. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 23:102.
47. Akiba, H., Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191:375.
48. Akiba, H., H. Oshima, K. Takeda, M. Atsuta, H. Nakano, A. Nakajima, C. Nohara, H. Yagita, and K. Okumura. 1999. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 162:7058.
49. Onodera, K., A. Chandraker, M. Schaub, T. H. Stadlbauer, S. Korom, R. Peach, P. S. Linsley, M. H. Sayegh, and J. W. Kupiec-Weglinski. 1997. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J. Immunol. 159:1711.
50. Valujskikh, A., B. Pantenburg, and P. S. Heeger. 2002. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am. J. Transplant. 2:501.
51. Judge, T. A., A. Tang, and L. A. Turka. 2002. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol. Res. 15:38.